STOCK TITAN

Cencora Inc. - COR STOCK NEWS

Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.

Cencora, Inc. (NYSE: COR) is a premier global pharmaceutical solutions provider committed to enhancing healthcare delivery and improving lives worldwide.

As one of the top three pharmaceutical wholesalers in the United States, Cencora specializes in sourcing and distributing branded, generic, and specialty pharmaceutical products to a diverse range of clients, including retail chains, independent pharmacies, mail-order services, hospital networks, and healthcare providers. In collaboration with McKesson and Cardinal Health, Cencora dominates over 90% of the U.S. pharmaceutical wholesale market.

Beyond its robust domestic operations, Cencora has significantly expanded its international footprint. Notably, the acquisition of Alliance Healthcare in 2021 bolstered its presence in Europe, making it one of the leading drug wholesalers in the region.

Additionally, Cencora offers comprehensive commercialization services for pharmaceutical and medical device manufacturers. Its global specialty drug logistics division, World Courier, is renowned for its precision and reliability. The company also extends its expertise to animal health product distribution through MWI Animal Health.

Cencora's strategic partnerships and innovative solutions drive operational efficiency, cost control, and growth opportunities across the healthcare supply chain.

  • Its pharmacy solutions enhance operational efficiency, cost control, growth opportunities, and patient safety.
  • Provider solutions focus on improving operational efficiency, financial performance, and quality of care.
  • Manufacturer solutions are designed to maximize success at every stage of the product lifecycle.


Recent achievements include a distribution agreement with Sapphiros, enhancing access to COVID-19 Antigen Rapid Tests and future diagnostic technologies in the U.S. market. This partnership is poised to bring innovative diagnostic solutions directly to patients, exemplifying Cencora's commitment to improving accessibility and convenience in healthcare.

Cencora’s mission is driven by a strong sense of purpose: 'We are united in our responsibility to create healthier futures.' Ranked #11 on the Fortune 500 and #24 on the Global Fortune 500, with annual revenues exceeding $250 billion, Cencora’s over 46,000 team members worldwide are dedicated to delivering positive health outcomes through their expertise and collaborative efforts.

Rhea-AI Summary
Sapphiros (COR) partners with Cencora, Inc. to distribute COVID-19 Antigen Rapid Tests and future diagnostic technologies, aiming to enhance accessibility and convenience for consumers nationwide. The agreement also includes access to upcoming Sapphiros technologies, such as multiplexed molecular diagnostics platform, rapid lateral flow tests for diseases beyond COVID-19, and the Satio™ blood collection patch in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) announces agreement to repurchase $250 million worth of common stock from Walgreens Boots Alliance Holdings LLC in concurrence with Rule 144 transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
buyback
-
Rhea-AI Summary
Walgreens Boots Alliance (WBA) announced the sale of shares of Cencora, Inc. (COR) through variable prepaid forward transactions, generating $424 million in current proceeds and potentially more at maturity. The company also conducted a concurrent share repurchase by Cencora for $250 million. The proceeds will be used for debt paydown and general corporate purposes, with no dilutive impact on adjusted EPS until the contracts mature in Q4 of fiscal year 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) reported a 12.7% YoY increase in revenue to $68.9 billion for Q4 2023. For the fiscal year 2023, revenue increased 9.9% to $262.2 billion. GAAP diluted EPS for Q4 was $1.72, while adjusted diluted EPS was $2.86. For the fiscal year, GAAP diluted EPS was $8.53 and adjusted diluted EPS was $11.99.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) plans to release Q4 2023 results on November 2, 2023, before the opening of trading on NYSE. Conference call to discuss results at 8:30 a.m. ET. Webcast available on investor.cencora.com. Replays available via telephone and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
-
Rhea-AI Summary
Cencora, Inc. completes name and stock ticker change, announces $5 million commitment to philanthropy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
Rhea-AI Summary

CoreSite Realty Corporation, a subsidiary of American Tower, announced tax reporting information for its 2021 distributions. Following the acquisition by American Tower on December 28, 2021, CoreSite's shares ceased trading on the NYSE. Stockholders are advised to consult tax advisors regarding their specific tax treatment. For the year, CoreSite reported cash distributions per share, including ordinary taxable dividends and capital gain distributions, emphasizing that there were no non-dividend distributions for the tax year ending December 28, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
Rhea-AI Summary

American Tower Corporation (NYSE: AMT) has successfully completed its acquisition of CoreSite Realty Corporation (NYSE: COR) following a tender offer for CoreSite's outstanding shares. The acquisition was financed through borrowings under American Tower’s credit facilities and term loans. CEO Tom Bartlett expressed optimism about leveraging CoreSite's data centers to enhance growth opportunities amidst the rise of 5G and cloud services. The acquisition is expected to be modestly accretive to American Tower’s AFFO per Share initially, with potential for increased accretion over time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Summary

American Tower Corporation (NYSE: AMT) announced the expiration of its tender offer for CoreSite Realty Corporation (NYSE: COR) shares, completing the acquisition via a merger with its subsidiary, Appleseed Merger Sub LLC. The tender offer, which ended on December 27, 2021, resulted in 31,443,126 shares tendered, accounting for approximately 71.15% of CoreSite's outstanding shares. CoreSite will merge into American Tower on December 28, 2021, with its shares ceasing to trade on the NYSE. Each CoreSite share will convert to $170.00 in cash, matching the tender offer price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
Rhea-AI Summary

CoreSite Realty Corporation (NYSE:COR) has announced that its VA3 data center is now powered by 100% renewable energy through Dominion Energy's 100% Renewable Energy Program. This initiative supports local renewable energy development in the Northern Virginia market. CoreSite aims to assist its customers in achieving their sustainability goals by offering a diverse energy portfolio, including solar, hydroelectric, and biomass sources. The VA3 facility, part of a larger data center campus, provides significant capacity and connectivity to major cloud providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Cencora (COR)?

The current stock price of Cencora (COR) is $241.43 as of February 21, 2025.

What is the market cap of Cencora (COR)?

The market cap of Cencora (COR) is approximately 47.2B.

What does Cencora, Inc. do?

Cencora, Inc. is a leading global pharmaceutical solutions provider, specializing in the sourcing and distribution of branded, generic, and specialty pharmaceuticals.

Who are Cencora's main clients?

Cencora serves retail chains, independent pharmacies, mail-order services, hospital networks, and healthcare providers.

What are some recent achievements of Cencora?

Cencora recently entered into a distribution agreement with Sapphiros to enhance access to COVID-19 Antigen Rapid Tests and future diagnostic technologies in the U.S.

How significant is Cencora in the U.S. pharmaceutical wholesale market?

Cencora, along with McKesson and Cardinal Health, constitutes over 90% of the U.S. pharmaceutical wholesale industry.

What international presence does Cencora have?

Cencora expanded its international presence by acquiring Alliance Healthcare in 2021, becoming a leading drug wholesaler in Europe.

What other services does Cencora provide?

Cencora offers commercialization services for pharmaceutical and medical device manufacturers, global specialty drug logistics, and animal health product distribution.

What is Cencora’s mission?

Cencora's mission is 'We are united in our responsibility to create healthier futures.'

How is Cencora ranked on the Fortune 500?

Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500.

What is the scale of Cencora's operations?

Cencora has over 46,000 employees worldwide and generates more than $250 billion in annual revenue.

What are some key solutions provided by Cencora?

Cencora provides pharmacy solutions for operational efficiency and patient safety, provider solutions for quality care, and manufacturer solutions for product lifecycle success.
Cencora Inc.

NYSE:COR

COR Rankings

COR Stock Data

47.16B
178.86M
10.67%
93.77%
4.47%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
CONSHOHOCKEN